u/A-Laine808

So, I thought it was my lucky evening to finally get my long awaited Dimoo with my rewards points. Joke is on me! The site and app will not let me redeem (yet up until 10:15 pm Hawaii time) the redeem option is still available. My app is updated. I tried using a different phone, browser, you name it, I tried it. I can not redeem button but it will not confirm my order as it appears that "Dimoo" has left the building. Like, he isn't even showing up in the rewards section either? How is this okay?

Yet I see so many trying to get rid of theirs for a pretty outrageous price and here I am, a loyal Dimoo fan, just trying to use the rewards I've earned to get me my free Dimoo after I spent way too much with Pop-Mart to even have this kind of issues. It brings me back to them Labubu days of horror and website and app issues.

I can't be the only one right that have experienced this issue? I feel so mad 😠 Like, turning red, MAD lol. Because he was that close to being home in Hawaii and I swear to you, he's still showing up on the notification link as an option to "Redeem" yet you can't.

Same Ole story with Pop-Mart. They not only fooled me in thinking I finally was around to get my reward but they've lost numerous of my orders in these past weeks on both their TikTok lives shows and purchases directly from their website.

Incoming screaming 😱 beware!

If it wasn't for bad luck, I'd have no luck at all.

Okay... back to go cry 😢 😭

​

I just got off the phone with Pomegranate Health. They told me that in order to receive medication I already paid for and was approved for, I now have to cover a $150 courier shipping fee. Since when? I never agreed to this.

I've ordered through Pomegranate before, and shipping was always included in the cost of the medication — no extra fees, ever. I begged Jo, the rep I spoke with, to make this right and cover the overhead cost. She refused, and when I asked to speak with a supervisor, she told me I'd hear the exact same answer.

I was given three options:

1. Pay the $150 to receive medication I was already approved for, prescribed, and paid for in full the day before, after signing all the required forms. As far as I'm concerned, that was a contract, and this cost should've been disclosed before I ever signed anything.

2. Switch to another provider/pharmacy (I won't name them), where shipping to Hawaii would cost $85 instead. Still not something I agreed to pay.

3. Take a full refund — which is the option I was left with, because I refuse to pay more than what I was told upfront.

I've used both Pomegranate and Pharmacy Hub before with zero issues shipping to Hawaii. So why, out of nowhere, are people in Hawaii and Alaska suddenly being hit with fees the rest of the country doesn't pay? No notice. No warning at sign-up. No mention that this could happen. I called Pharmacy Hub myself to ask when this policy went into effect, and no one could give me a straight answer.

Both companies say they have no control over what the courier charges — fine. But this isn't the first time I've shipped to Hawaii through them, so I don't understand why neither company is willing to absorb the overhead cost instead of passing it straight to the customer. This isn't even expedited shipping. It's standard delivery that, until now, was already built into the price.

All I got was an "I'm sorry for the inconvenience" and no real solution. I paid for my order. I should be able to receive it under the terms I agreed to — not new terms sprung on me after the fact.

Consider this a heads-up to my fellow Hawaii and Alaska friends: shipping fees like this are starting to show up out of nowhere, apparently due to rising courier costs providers are passing straight to customers instead of absorbing themselves. Watch your invoices, and don't be afraid to push back and ask questions before you pay.

FDA proposes ban on bulk compounding of semaglutide and tirzepatide

**THIS IS THE TIME FOR ALL OF US TO SUBMIT OUR COMMENTS FOR OR AGAINST THIS DECISION. LET'S BAND TOGETHER AND LET OUR VOICES BE HEARD**

Based on the FDA’s announcement regarding the proposal to exclude compounded semaglutide, tirzepatide, and liraglutide from the 503B bulks list, public comments for or against this decision must be submitted by June 29, 2026. [1, 2]

Comments can be submitted either electronically or by mail:

• Electronic Submission: Use the Federal eRulemaking Portal at www.regulations.gov and search for the docket number FDA-2026-N-2431.

• Mail/Hand Delivery/Courier: Send written comments to:

Dockets Management Staff (HFA-305)

Food and Drug Administration

5630 Fishers Lane, Room 1061

Rockville, MD 20852

[4, 6, 7]

Important Tips for Submitting Comments:

• Include Docket Number: All submissions must include the docket number FDA-2026-N-2431 to ensure it is considered.

• Deadline: Comments must be received by 11:59 p.m. Eastern Time on June 29, 2026.

• Public Visibility: All comments are public and will be posted at www.regulations.gov. Do not include confidential or private information.

The FDA will review these comments to determine if there is a demonstrated "clinical need" to keep these drugs available from 503B outsourcing facilities before issuing a final decision. [1]

AI responses may include mistakes.

[1] https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

[2] https://www.newswire.com/news/altrx-glp-1-review-2026-updated-for-the-latest-fda-compounded-semaglutide

[3] https://www.federalregister.gov/documents/2026/03/19/2026-05329/agency-information-collection-activities-proposed-collection-comment-request-premarket-notifications

[4] https://www.federalregister.gov/documents/2026/04/10/2026-06906/agency-information-collection-activities-proposed-collection-comment-request-premarket-approval-of

[5] https://www.fda.gov/animal-veterinary/cvm-updates/fda-announces-2026-virtual-public-meetings-and-comment-periods-reauthorization-user-fee-programs

[6] https://www.federalregister.gov/documents/2026/04/07/2026-06719/agency-information-collection-activities-proposed-collection-comment-request-administrative

[7] https://www.healthlawadvisor.com/fda-proposal-would-leave-semaglutide-tirzepatide-and-liraglutide-off-503b-bulks-list

[8] https://www.regulations.gov/document/FDA-2026-N-1736-0001

[9] https://www.fda.gov/food/workshops-meetings-webinars-food-and-dietary-supplements/public-meeting-exploring-scope-dietary-supplement-ingredients-03272026